{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-22-007076","form_type":"8-K","ticker":"JYNT","cik":"0001612630","company_name":"JOINT Corp","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.403124+00:00","generated_at":"2026-06-22T09:08:10.097952+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"The Joint Corp Q3 revenue +27% to $26.6M; net income drops to $491k; lowers EBITDA guidance","bullets":["Revenue $26.6M (+27% YoY); net income $491k ($0.03 EPS) vs $1.9M ($0.13) in Q3 2021.","System-wide sales $110.4M (+18%); system-wide comp sales +6%; 38 clinics opened in quarter.","Total clinics 805 (690 franchised, 115 company-owned/managed) at Sept 30, 2022.","Adjusted EBITDA $3.1M vs $3.3M last year; 2022 guidance: revenue $100-102M, EBITDA $11.5-12.5M (lowered from $12-14M).","Reacquired Philadelphia RD territory; acquired 2 clinics and sold 1 corporate clinic post-quarter."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-22-007076","json":"https://secwatch.observer/filing/0001171843-22-007076.json","markdown":"https://secwatch.observer/filing/0001171843-22-007076.md","text":"https://secwatch.observer/filing/0001171843-22-007076.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1612630/000117184322007076/0001171843-22-007076-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1612630/000117184322007076/f8k_110322.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T09:08:10.097952+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0934e0a0e549ca0a7906bd4525883ec82fa37fc2","claim":"JOINT Corp reported the nine months ended September 30, 2022 results: revenue $74.1 million, net income $630,000, EPS $0.04 per diluted share.","evidence_excerpt":"Revenue was $74.1 million in the first nine months of 2022, compared to $58.8 million in the first nine months of 2021. Net income was $630,000, or $0.04 per diluted share, compared to $6.9 million, or $0.46 per diluted share, in the first nine months of 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1612630/000117184322007076/0001171843-22-007076-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the nine months ended September 30, 2022"},{"label":"Revenue","value":"$74.1 million"},{"label":"Net income","value":"$630,000"},{"label":"EPS","value":"$0.04 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"4adeb5630c3d99b8f086b2ca96655be32ecf5ce1","claim":"JOINT Corp reported the quarter ended September 30, 2022 results: revenue $26.6 million, net income $491,000, EPS $0.03 per diluted share.","evidence_excerpt":"Grew revenue 27% to $26.6 million. Recorded operating income of $500,000, compared to $1.3 million. Reported net income of $491,000, compared to $1.9 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1612630/000117184322007076/0001171843-22-007076-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Revenue","value":"$26.6 million"},{"label":"Net income","value":"$491,000"},{"label":"EPS","value":"$0.03 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}